Skip to main content
Premium Trial:

Request an Annual Quote

Funding Update: NSF Grants Awarded to Ohio State, University of Rochester

Premium

Recent NSF Awards in Proteomics and Protein Research

Title: Scalable Nanomanufacturing of Cyclic Peptide-Based Nanorobots for In Vivo Sensing
Principal Investigator: Mingjun Zhang
Sponsor: Ohio State University
Start/End Date: Jan. 1, 2014 – Aug. 31, 2016
Amount Awarded to Date: $288,948

Funds the development of a nanomanufacturing platform for fabricating cyclic peptide-based nanorobots for biomedical applications. The robots will consist of peptide-based nanotubes connected with DNA-based aptamers that will serve as biosensors for purposes including biomarker detection and targeted drug discovery.


Title: Global Analysis of In Vivo Protein Folding Efficiencies by Mass Spectrometry
Principal Investigator: Sina Ghaemmaghami
Sponsor: University of Rochester
Start/End Date: Jan. 1, 2014 – Dec. 31, 2018
Amount Awarded to Date: $190,000

Funds development of mass spec techniques for quantifying the proportion of proteins that successfullly fold in a cell after protein synthesis with the larger aim of studying folding efficiencies of different proteins and identifying relationships between the physical properties of a protein and their propensity to fold properly.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.